Early identification of refractory epilepsy
- PMID: 10660394
- DOI: 10.1056/NEJM200002033420503
Early identification of refractory epilepsy
Abstract
Background: More than 30 percent of patients with epilepsy have inadequate control of seizures with drug therapy, but why this happens and whether it can be predicted are unknown. We studied the response to antiepileptic drugs in patients with newly diagnosed epilepsy to identify factors associated with subsequent poor control of seizures.
Methods: We prospectively studied 525 patients (age, 9 to 93 years) who were given a diagnosis, treated, and followed up at a single center between 1984 and 1997. Epilepsy was classified as idiopathic (with a presumed genetic basis), symptomatic (resulting from a structural abnormality), or cryptogenic (resulting from an unknown underlying cause). Patients were considered to be seizure-free if they had not had any seizures for at least one year.
Results: Among the 525 patients, 333 (63 percent) remained seizure-free during antiepileptic-drug treatment or after treatment was stopped. The prevalence of persistent seizures was higher in patients with symptomatic or cryptogenic epilepsy than in those with idiopathic epilepsy (40 percent vs. 26 percent, P=0.004) and in patients who had had more than 20 seizures before starting treatment than in those who had had fewer (51 percent vs. 29 percent, P<0.001). The seizure-free rate was similar in patients who were treated with a single established drug (67 percent) and patients who were treated with a single new drug (69 percent). Among 470 previously untreated patients, 222 (47 percent) became seizure-free during treatment with their first antiepileptic drug and 67 (14 percent) became seizure-free during treatment with a second or third drug. In 12 patients (3 percent) epilepsy was controlled by treatment with two drugs. Among patients who had no response to the first drug, the percentage who subsequently became seizure-free was smaller (11 percent) when treatment failure was due to lack of efficacy than when it was due to intolerable side effects (41 percent) or an idiosyncratic reaction (55 percent).
Conclusions: Patients who have many seizures before therapy or who have an inadequate response to initial treatment with antiepileptic drugs are likely to have refractory epilepsy.
Similar articles
-
[Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy].Rev Neurol (Paris). 2001 May;157(5):525-36. Rev Neurol (Paris). 2001. PMID: 11438772 Clinical Trial. French.
-
Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study.JAMA Neurol. 2018 Mar 1;75(3):279-286. doi: 10.1001/jamaneurol.2017.3949. JAMA Neurol. 2018. PMID: 29279892 Free PMC article.
-
Does the cause of localisation-related epilepsy influence the response to antiepileptic drug treatment?Epilepsia. 2001 Mar;42(3):357-62. doi: 10.1046/j.1528-1157.2001.29000.x. Epilepsia. 2001. PMID: 11442153
-
Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis.Lancet Neurol. 2017 Jul;16(7):523-531. doi: 10.1016/S1474-4422(17)30114-X. Epub 2017 May 5. Lancet Neurol. 2017. PMID: 28483337 Review.
-
Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.Cochrane Database Syst Rev. 2015 Aug 14;(8):CD001911. doi: 10.1002/14651858.CD001911.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2017 Feb 27;2:CD001911. doi: 10.1002/14651858.CD001911.pub3. PMID: 26275105 Updated. Review.
Cited by
-
Late-onset drug-resistant epilepsy in pyridoxamine 5'-phosphate oxidase deficiency: a case report.J Med Case Rep. 2024 Nov 15;18(1):542. doi: 10.1186/s13256-024-04876-7. J Med Case Rep. 2024. PMID: 39543701 Free PMC article.
-
Efficacy and safety of transcranial direct current stimulation (tDCS) in treatment of refractory epilepsy: an updated systematic review and meta-analysis of randomized sham-controlled trials.Neurol Sci. 2024 Nov 13. doi: 10.1007/s10072-024-07866-1. Online ahead of print. Neurol Sci. 2024. PMID: 39532798 Review.
-
The Best Things Happen When You Least Expect Them: Responsive Neurostimulation During Low-Risk Brain States is Associated with Improved Long-Term Seizure Suppression.Epilepsy Curr. 2024 Jun 14;24(5):350-352. doi: 10.1177/15357597241258287. eCollection 2024 Sep-Oct. Epilepsy Curr. 2024. PMID: 39508007 Free PMC article. No abstract available.
-
From seizure to stability: unveiling the brain's network changes with anti-seizure medication.Brain Commun. 2024 Sep 27;6(5):fcae335. doi: 10.1093/braincomms/fcae335. eCollection 2024. Brain Commun. 2024. PMID: 39440301 Free PMC article.
-
Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder.Int J Mol Sci. 2024 Oct 7;25(19):10768. doi: 10.3390/ijms251910768. Int J Mol Sci. 2024. PMID: 39409097 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical